MITO 35b Olaparib beyond progression compared to platinum chemotherapy after secondary cytoreductive surgery in recurrent ovarian cancer patients. The phase III randomized, open label MITO 35b study: a project of the MITO-MANGO groups.

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516842-21-00

Enrollment

200

Registered

2025-01-09

Start date

2025-01-09

Completion date

Unknown

Last updated

2025-07-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent ovarian cancer

Brief summary

1)progression-free survival 2) progression-free survival 2

Detailed description

1) Overall Survival 2) Safety and tolerability (CTCAE 5.0 version and PRO-CTCAE questionnaire) 3) Quality of Life (EORTC QLQ-C30 questionnaire) 4) Financial toxicity (PROFFIT questionnaire

Interventions

DRUGCISPLATIN

DRUGLynparza 150 mg film-coated tablets

DRUGDOXORUBICIN

DRUGPACLITAXEL

DRUGGEMCITABINE

DRUGBEVACIZUMAB

DRUGLynparza 100 mg film-coated tablets

DRUGCARBOPLATIN

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
1)progression-free survival 2) progression-free survival 2	—

Secondary

Measure	Time frame
1) Overall Survival 2) Safety and tolerability (CTCAE 5.0 version and PRO-CTCAE questionnaire) 3) Quality of Life (EORTC QLQ-C30 questionnaire) 4) Financial toxicity (PROFFIT questionnaire	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026